Halozyme Therapeutics, Inc. - Common Stock (HALO)
63.02
+1.15 (1.86%)
NASDAQ · Last Trade: Apr 2nd, 11:33 PM EDT
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) qualifies as a high growth stock. A fundamental and technical analysis of (NASDAQ:HALO).
Via Chartmill · March 31, 2025
Based on a technical and fundamental analysis of NASDAQ:HALO we can say: HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.
Via Chartmill · March 27, 2025
HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.
Via Chartmill · March 14, 2025
HALOZYME THERAPEUTICS INC has a stellar value proposition. NASDAQ:HALO not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.
Via Chartmill · March 11, 2025

Exploring HALOZYME THERAPEUTICS INC's Technical Signals and Breakout Potential: A technical analysis of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) shows it may be setting up for a breakout.
Via Chartmill · March 6, 2025

Via Benzinga · February 20, 2025

Via Benzinga · February 4, 2025

Based on a technical and fundamental analysis of NASDAQ:HALO we conclude: HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill · February 26, 2025

HALOZYME THERAPEUTICS INC could be undervalued. NASDAQ:HALO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.
Via Chartmill · February 17, 2025

Discover HALOZYME THERAPEUTICS INC, an undervalued stock. NASDAQ:HALO showcases solid financial health and profitability while maintaining an appealing valuation.
Via Chartmill · February 17, 2025

A fundamental and technical analysis of (NASDAQ:HALO): HALOZYME THERAPEUTICS INC (NASDAQ:HALO) may be suited for high growth investing, we'll explore why in this article.
Via Chartmill · February 3, 2025

Based on fundamental and technical analysis of NASDAQ:HALO we ask: Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill · February 3, 2025

HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.
Via Chartmill · January 27, 2025

Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill · December 18, 2024

Via Benzinga · December 18, 2024

NASDAQ:HALO, a growth stock which is not overvalued.
Via Chartmill · December 16, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill · January 24, 2025

One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.
Via Investor's Business Daily · January 15, 2025

BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.
Via Investor's Business Daily · January 14, 2025

The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.
Via Investor's Business Daily · January 8, 2025

Don't overlook HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill · January 6, 2025

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.
Via Chartmill · January 3, 2025

For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals.
Via Chartmill · December 13, 2024